Integra LifeSciences Holdings Co. (NASDAQ:IART) is Sapience Investments LLC's 6th Largest Position

Sapience Investments LLC raised its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 17.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 164,775 shares of the life sciences company's stock after purchasing an additional 24,830 shares during the period. Integra LifeSciences makes up about 2.2% of Sapience Investments LLC's investment portfolio, making the stock its 6th biggest holding. Sapience Investments LLC owned about 0.21% of Integra LifeSciences worth $3,737,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in IART. Quadrant Capital Group LLC grew its position in shares of Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after purchasing an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after buying an additional 2,800 shares during the last quarter. Covestor Ltd raised its position in shares of Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after acquiring an additional 2,071 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in Integra LifeSciences in the fourth quarter worth approximately $180,000. Institutional investors own 84.78% of the company's stock.

Analysts Set New Price Targets

IART has been the topic of a number of research analyst reports. Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. JMP Securities reduced their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Wells Fargo & Company cut their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Finally, JPMorgan Chase & Co. cut their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $18.63.

Integra LifeSciences Trading Down 0.9%

IART stock traded down $0.12 during trading on Thursday, hitting $12.58. 542,830 shares of the company traded hands, compared to its average volume of 1,040,948. The company has a 50-day moving average of $17.45 and a 200-day moving average of $21.54. Integra LifeSciences Holdings Co. has a 1 year low of $11.60 and a 1 year high of $32.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm has a market capitalization of $977.23 million, a PE ratio of -139.71, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same period in the prior year, the company posted $0.55 EPS. The firm's revenue was up 3.7% on a year-over-year basis. Analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.